Pay in 4 interest-free payments of $5.74 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
BPC 157 entered early-phase clinical development for inflammatory bowel disease as PL 14736 (Pliva, Croatia), and a 2025 pilot examined intravenous administration in a small cohort, but no adequately powered randomised controlled trial exists
Cognitive changes such as memory problems, brain fog, or difficulty concentrating
However, Partnership for Safe Medicines Executive Director Shabbir Imber Safdar stated that these votes are a serious setback for patient safety," adding that the Pharmaceutical Compounding Advisory Committee voted to advance substances that FDAs own scientists flagged as lacking adequate evidence of safety, efficacy, or quality
The overall quality of evidence for this outcome was low due to serious imprecision (low number of trials and participants)
US$ 27.03
US$ 24.05
US$ 28.69
